| Q47162185 | "Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty". |
| Q92336127 | A Comprehensive Review of Ovarian Serous Carcinoma |
| Q37781970 | A Pathologist's Road Map to Benign, Precancerous, and Malignant Intraepithelial Proliferations in the Fallopian Tube |
| Q33850471 | A Resident's Perspective of Ovarian Cancer |
| Q87399727 | A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers |
| Q33668934 | Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers |
| Q80731965 | Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries |
| Q81299131 | Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense? |
| Q35219159 | Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer |
| Q37676705 | Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis |
| Q38437730 | Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations |
| Q85068531 | Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin? |
| Q92950797 | Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma |
| Q37513137 | BRCA and Early Events in the Development of Serous Ovarian Cancer. |
| Q34345297 | BRCA1 and BRCA2: 1994 and beyond |
| Q34970470 | BRCA1: mechanisms of inactivation and implications for management of patients |
| Q91473485 | Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma |
| Q59809876 | Cell Origins of High-Grade Serous Ovarian Cancer |
| Q51842388 | Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. |
| Q34568554 | Clinical management of BRCA1 and BRCA2 mutation carriers |
| Q36754871 | Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation |
| Q34313361 | Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up |
| Q34378112 | Coming into focus: the nonovarian origins of ovarian cancer. |
| Q37729985 | Complications from Surgeries Related to Ovarian Cancer Screening |
| Q46109381 | Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation |
| Q42881236 | Costs of prophylactic resection. |
| Q26852127 | Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR) |
| Q34595670 | Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma |
| Q34125241 | Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? |
| Q82682167 | Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube? |
| Q45363855 | E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium. |
| Q34094731 | Early detection of ovarian cancer |
| Q34714707 | Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma |
| Q53664165 | Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology. |
| Q35560963 | Fallopian tube correlates of ovarian serous borderline tumors |
| Q46560077 | Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis |
| Q37468316 | Genetic risk and gynecologic cancers. |
| Q50980879 | Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors. |
| Q37192947 | Gynecologic cancers associated with Lynch syndrome/HNPCC. |
| Q83525183 | Hereditary breast and ovarian cancer syndrome |
| Q36884728 | Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis |
| Q34977063 | Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management |
| Q92839824 | High-grade serous ovarian and fallopian tube carcinomas with similar clinicopathological characteristics might originate from serous tubal intraepithelial carcinoma in Chinese women |
| Q34152848 | Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer |
| Q36111438 | Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations |
| Q85645318 | It sounded like a good idea at the time |
| Q36369334 | Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study |
| Q35758403 | Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. |
| Q35132433 | Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma |
| Q42365263 | Loss of calponin h1 confers anoikis resistance and tumor progression in the development of high-grade serous carcinoma originating from the fallopian tube epithelium |
| Q83597688 | Low-grade serous primary peritoneal carcinoma |
| Q47213635 | MRI findings for primary fallopian tube cancer: correlation with pathological findings. |
| Q34625221 | Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis |
| Q35140600 | Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm |
| Q85096106 | Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases |
| Q37119411 | New insights into the pathogenesis of serous ovarian cancer and its clinical impact |
| Q76383194 | Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy |
| Q51819338 | Occult endometrial cancer and decision making for prophylactic hysterectomy in hereditary nonpolyposis colorectal cancer patients. |
| Q37577667 | Oncofertility in Canada: cryopreservation and alternative options for future parenthood |
| Q36938143 | Opportunistic salpingectomy for ovarian cancer prevention |
| Q86761473 | Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: the time has come |
| Q36068263 | Origins and molecular pathology of ovarian cancer |
| Q33850454 | Ovarian Cancer Incidence Corrected for Oophorectomy |
| Q26747279 | Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention |
| Q39421659 | Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening |
| Q80235342 | Ovarian cancer: an update |
| Q26822545 | Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis |
| Q53206369 | PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. |
| Q37546692 | Pathogenesis and heterogeneity of ovarian cancer. |
| Q30370475 | Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. |
| Q91676333 | Peritoneal cancer after bilateral mastectomy, hysterectomy, and bilateral salpingo-oophorectomy with a poor prognosis: A case report and review of the literature |
| Q35934073 | Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations |
| Q39441988 | Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention |
| Q33815261 | Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics |
| Q36173170 | Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype |
| Q34081146 | Preservation of fertility in patients with cancer |
| Q46366935 | Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube |
| Q36897728 | Preventing ovarian cancer by salpingectomy. |
| Q88990730 | Primary carcinoma of the fallopian tubes: Analysis of sixteen patients |
| Q37042357 | Primary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo-oophorectomy |
| Q37741774 | Probability of fallopian tube and ovarian detection with transvaginal ultrasonography in normal women |
| Q34407218 | Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review |
| Q37853691 | Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development |
| Q30250107 | Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence |
| Q79864098 | Recommendations for the reporting of fallopian tube neoplasms |
| Q34811314 | Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations |
| Q87293688 | Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later |
| Q82532746 | Role of prophylactic hysterectomy in patients at high risk for hereditary cancers |
| Q89923260 | Serous tubal intraepithelial neoplasia: the concept and its application |
| Q81890073 | Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy |
| Q88361835 | Survey of pelvic reconstructive surgeons on performance of opportunistic salpingectomy at the time of pelvic organ prolapse repair |
| Q28302089 | The cell of origin of ovarian epithelial tumours |
| Q30240709 | The disparate origins of ovarian cancers: pathogenesis and prevention strategies. |
| Q38187331 | The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift |
| Q36810356 | The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms |
| Q34288214 | The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. |
| Q33739695 | The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory |
| Q27025315 | The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention" |
| Q33487678 | The preclinical natural history of serous ovarian cancer: defining the target for early detection |
| Q61925515 | The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer |
| Q35591610 | Three-dimensional modeling of ovarian cancer. |
| Q34911178 | To transplant or not to transplant - that is the question |
| Q26771979 | Toward precision medicine for preserving fertility in cancer patients: existing and emerging fertility preservation options for women |
| Q84401609 | Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls |
| Q36799895 | Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type |
| Q33687535 | Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry? |
| Q33850475 | Ultrasound Monitoring of Extant Adnexal Masses in the Era of Type 1 and Type 2 Ovarian Cancers: Lessons Learned From Ovarian Cancer Screening Trials |
| Q37331949 | Vitamin A metabolism is impaired in human ovarian cancer |